Inhaler monitoring company Propeller Health has announced that it will develop an add-on sensor for Novartis’s Breezhaler DPI. The sensor, which will be used on COPD products Ultibro, Onbrez, and Seebri Breezhaler in Europe, will record patient use data and transmit that data through the Propeller platform.
The company is already partnered with a number of pharmaceutical companies, including GSK, Vectura, and Boehringer Ingelheim. In February 2016, Propeller announced that it had partnered with Aptar Pharma to develop a connected MDI.
Propeller Health CEO David Van Sickle commented, “We’re excited to work with the team at Novartis to connect the Breezhaler device to the Propeller platform. The addition of this major respiratory franchise represents an important next step in our mission to bring valuable digital companions to everyone’s respiratory treatments. With data from these medication sensors and interfaces, Propeller strengthens the relationships between patients and their physicians and helps them build effective treatment programs together.”
Read the Propeller Health press release.
